Clinical Trial

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

Name: Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel — clinical trial record (NCT04514419)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2020-08-12.

Status change: Recruiting → Active, Not Recruiting 2025-11-18

Trial Details

NCT Number	NCT04514419
Lead Sponsor	BioRay Pharmaceutical Co., Ltd.
Conditions	Breast Cancer
Enrollment	408 participants
Start Date	2020-06-28
Primary Completion	2024-09-11 (estimated)
Study Completion	2025-12 (estimated)
Updated on ClinicalTrials.gov	2025-11-21